Showing 111-120 of 2094 results for "".
Physician Spotlight: Roy Geronemus, MD
https://practicaldermatology.com/columns/physician-spotlight/physician-spotlight-roy-geronemus-md/23151/Physician Spotlight: Gary Goldenberg, MD
https://practicaldermatology.com/columns/physician-spotlight/physician-spotlight-gary-goldenberg-md/20897/Perspective on the dermatologist's role in recommending lifestyle changes with patients.Approval for Evolus; Remembering Vic Narurkar, MD
https://practicaldermatology.com/topics/practice-management/dermwiretv-approval-for-evolus-remembering-vic-narurkar-md/19553/The FDA has approved Jeuveau, the lead product from Evolus, Inc. David Moatazedi, President and CEO of Evolus, and Michael Jafar, Chief Marketing Officer at Evolus, comment on market potential for the new product.Twenty-eight percent of physicians say the prior authorization process required by healConsiderations for Treatment Downtime After Laser Therapy in Scar Repair
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/considerations-for-treatment-downtime-after-laser-therapy-in-scar-repair-/18625/E. Victor Ross, MD discusses how treatment downtime influences his approach for treating scars. His goal, he said, is to achieve the highest degree of efficacy possible with laser used as mono- or combination therapy while being mindful of patients' comfort levels with the associated recovery periodEmerging Vitiligo Therapies
https://practicaldermatology.com/conferences/maui-derm-2022/emerging-vitiligo-therapies/20047/It’s really an exciting time to be treating vitiligo, says John E. Harris, MD, PhD. He reviews Phase 2 and 3 clinical trials for ruxolitinib, a topical JAK inhibitor, and the hope that the FDA could soon approve it for the treatment of vitiligo. He also discusses other possible targeted treatments iThe Case for JAK Inhibitors to Treat AD
https://practicaldermatology.com/topics/atopic-dermatitis/case-jak-inhibitors-treat-ad/27109/E. James Song, MD, FAAD, Director of Clinical Research and Co-Chief Medical Officer for Frontier Dermatology, discusses his presentation “JAK Inhibitors in Atopic Dermatitis” from the 2024 American Academy of Dermatology (AAD) Innovation Academy.Skin of Color Session: Dr. Harris
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/skin-of-color-session-dr-harris/32683/John E. Harris, MD, PhD, summarizes his vitiligo talk from the "Skin of Color Session" at Maui Derm 2025, during which he covered new therapeutic options for vitiligo as well as promising drugs in the pipeline and why they could be so impactful.Cracking the Codes: Telemedicine Rolls Forward
https://practicaldermatology.com/topics/practice-management/cracking-the-codes-telemedicine-rolls-forward/23226/Here’s a primer on the new online digital E/M service codes.Think Before You Sync
https://practicaldermatology.com/topics/practice-management/think-before-you-sync/20929/Is your next e-purchase digital snake oil or the real deal?Nordlys™: A Foundational Platform For Your Practice
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/nordlys-a-foundational-platform-for-your-practice/19628/Don’t miss this informative webinar with E. Victor Ross, MD about his experience with the Nordlys system. Nordlys includes 3 foundational technologies: Ellipse IPL, Frax 1550, and Nd:Yag 1064. The benefits of narrowband IPL with dual filters and sub-millisecond pulses will be examined. Dr. Ross will